BioSpace News Archive

Laekna announced reporting the results of a phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in patients with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies at the 2023 San Antonio Breast Cancer Symposium on December 8.

WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has commenced its Quantitative Sensory Testing (QST) clinical trial and is actively recruiting participants into this clinical trial.

Cytovance Biologics has announced a strategic collaboration with fellow CDMO Alcami Corporation to expand its large molecule biologic manufacturing and sterile fill finish offering.

NRx Pharmaceuticals, Inc. today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8th through the 10th in San Francisco.

Hemab Therapeutics announced today that it has completed Phase 1, the single ascending dose part, and transitioned to Phase 2, the multiple ascending dose part, of its Phase 1/2 clinical study of HMB-001 in Glanzmann Thrombasthenia (GT), a platelet disorder that causes severe, potentially life-threatening bleeding episodes.

Acurx Pharmaceuticals, Inc. today announced positive Phase 2b results showing 100% of CDI patients who had CC with ibezapolstat, the company’s late-stage antibiotic candidate, also had SCC.

Electra Therapeutics, Inc. today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.

Regeneron Pharmaceuticals, Inc. announced its inclusion on the Dow Jones Sustainability World Index for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index.

Cogent Biosciences, Inc. today reported positive data from Part 1 of the Company’s ongoing Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) at the 65th American Society of Hematology (ASH 2023) Annual Meeting & Exposition taking place December 9-12, 2023 in San Diego, CA.

Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024.